Rznomics, a pioneer in RNA editing, is developing anticancer and rare disease therapies using its proprietary Trans-Splicing Ribozyme (TSR) platform—the first of its kind to enter clinical trials. The company aims to go public on KOSDAQ by 2025 via a special track. CEO Seong-Wook Lee envisions TSR as a game-changing technology, with near-term plans for licensing and tech evaluation.

Founded in 2017 by Dr. Lee after two decades of research, Rznomics has overcome early challenges in RNA delivery and efficacy to establish strong preclinical and clinical pipelines. TSR’s key strength lies in its ability to replace defective RNA without altering DNA, offering higher precision and fewer off-target effects than CRISPR.

Lead candidate RZ-001 is in Phase 1b/2a trials for liver and brain cancers and has received FDA Orphan Drug Designation and Fast Track status. Rznomics is also advancing RZ-004 for retinitis pigmentosa, capable of addressing all rhodopsin mutations—a first in the field.

In addition, Rznomics is developing a novel circular RNA platform, showing improved stability and expression compared to conventional methods. With a team of seasoned experts, the company is positioning TSR as a new global standard for RNA-based therapies.

Source:https://rznomics.com/bbs/so_table=promote_en&mode=VIEW&num=112&category=&findType=&findWord=&sort1=&sort2=&page=1&PHPSESSID=efd54e76267ab33bdf368aba4ea9c763